Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Safety and efficacy of a modified-live canine coronavirus vaccine in dogs

A. Pratellia, A. Tinellia, N. Decaroa, V. Martellaa, M. Camerob, M. Tempesta6, M. Martini6, L.E. Carmichaelc, C. Buonavogliaa

a Department of Animal Health and Well-being, Faculty of Veterinary Medicine, Strada per Casamassima km 3, 70010 Valenzano, Bari, Italy
b Department of Public Health, Comparative Pathology and Veterinary Hygiene, Faculty of Veterinary Medicine, Padua, Italy
c James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA

Received 7 March 2003; received in revised form 10 July 2003; accepted 21 July 2003

Abstract

The safety and the efficacy of a modified-live (ML) canine coronavirus (CCoV) vaccine strain 257/98-3c was evaluated in 14 dogs seronegative and virus negative for CCoV. For the safety test, four dogs were inoculated, two by intramuscular and two by oronasal route, with 10 times the vaccinal dose. During the observation period (28 days) all dogs did not display any local or systemic reaction. For the efficacy test, eight dogs were vaccinated by intramuscular (four dogs—group A) or by oronasal route (four dogs—group B). Two dogs were maintained as non-vaccinated controls. In the dogs of group A, vaccinal virus was not detected in faecal samples by virus isolation (VI) and by PCR assay, while in the dogs of group B, the virus was revealed for six median days only by PCR. Twenty-eight days later, the vaccinated and control dogs were challenged with a field CCoV strain. After the challenge, the vaccinated dogs did not display clinical signs and the dogs of group A shed virus for 5.5 median days, evaluated by VI, and for 10 median days evaluated by PCR. Virus shedding was not observed, both by VI and PCR assay, in the dogs of group B. The two control dogs displayed moderate clinical signs and the virus was detected by VI for 14.5 median days starting from day 3 post-challenge (dpc 3) and by PCR assay for 23 median days starting from dpc 1.

© 2003 Elsevier B.V. All rights reserved.

Keywords: Canine coronavirus; Vaccine; Efficacy

1. Introduction

Coronaviruses are positive-stranded RNA viruses recently classified in the order Nidovirales, mainly on the basis of their genomic organization and their replication strategy (de Vries et al., 1997). The coronavirus genome consists of a large open reading frame (ORF) at the 5'-end which encodes the replicase gene (ORF1a and ORF1b). Downstream from the replicase gene, there are smaller ORFs which encode the structural proteins S, E, M, the nucleocapsid (N) protein and a number of presumptive non-structural proteins of largely unknown function (Luytjes, 1995).

Most research has focused on the S protein as a candidate antigen for coronavirus vaccines, since it is the major inducer of virus-neutralizing antibodies (Gebauer et al., 1991). The function of the M protein is still not clear. Although a major immunological role...
has been attributed to the S protein, both the amino- and the carboxy-termini of the M protein elicit strong immune responses (Enjuanes et al., 2000), inducing antibody-dependent, complement-mediated, virus neutralization (VN) (Woods et al., 1987).

The role of CCoV in inducing enteric illness in canids has been the subject of active investigation for over two decades. The virus is responsible for mild to moderate enteritis in dogs; in young pups, or in combination with other pathogens, illness may be severe with diarrhea, vomiting, dehydration, loss of appetite and even death (Evermann et al., 1980; Appel, 1988). Shedding of CCoV in faeces occurs over a range of 6–14 days post-infection (Keenan et al., 1976; Tennant et al., 1991), however, faecal shedding in infected pups has been detected by n-PCR for periods from 37 to 150 days (Pratelli et al., 2001, 2002a). The value of CCoV vaccines in providing adequate immunity under field conditions is controversial. Although the efficacy and the duration of immunity engendered by inactivated vaccines have not been substantiated, killed CCoV vaccines have been licensed in the USA. In a recent study, the low efficacy of an inactivated CCoV vaccine in reducing the viral shedding in faeces of dogs after CCoV infection is described (Pratelli et al., 2003). A modified-live (ML) CCoV vaccine was licensed in USA in 1983, but was rapidly withdrawn due to a high rate (about 5%) of serious adverse reactions (Martin, 1985; Wilson et al., 1986). A ML CCoV vaccine, available in California and recently licensed in USA, appears to be safe and 1-year duration of immunity is claimed by the manufacturer. Unfortunately, the CCoV vaccine, when combined with canine cell-grown distemper vaccine (Rockborn strain), resulted in a high frequency of post-distemper encephalitis (Carmichael, 1997).

2. Materials and methods

2.1. Animals

Fourteen conventional dogs, 3 months of age were used. They were negative for CCoV antigen in the faeces, and CCoV antibodies before the experiment. Baseline body temperature and white blood cell (WBC) count were established for each dog averaging the results of the 3 days before vaccination. The experimental study was performed according to the animal health and well-being regulations and was authorized by the Minister of Health of Italy (authorization no. 67/2002-C).

2.2. Vaccine

A modified-live CCoV vaccine, strain 257/98-3c, was used. The virus was originally isolated from a faecal sample of a dog with mild enteritis and was serially passed 40 times on canine cells (A-72). The virus at the 40th passage had an infectivity titer of $10^{4.50}$ TCID$_{50}$/H9262 and was used throughout the study. The stock vaccine had been tested for sterility from aerobe and anaerobe bacteria, mycoplasmas, mycetes and contaminant viruses using standardized methods.

2.3. Safety test

To test the safety of the ML CCoV vaccine, four dogs (nos. 1–4) were inoculated, two by intramuscular (nos. 1 and 2) and two by oronasal route (nos. 3 and 4), with 10 times the vaccinal dose inoculated in the efficacy test. Following inoculation, dogs were individually isolated and daily observed for 28 days for signs of illness, WBC count and body temperature. For virological assays, individual faecal samples were collected from 3 days before the test through day 28. On day 28 all dogs were bled for serology.

2.4. Challenge

The field CCoV strain 144/01 was isolated from a faecal sample of a diarrhoeic pup (Marsilio et al., 2002) and was used to challenge the dogs. The virus was propagated on primary canine embryonic kidney (CEK) cells for three passages and stored at $-70\, ^\circ\text{C}$. All dogs (immunized and control) were challenged 28 days after vaccination. Each animal received 4 ml of viral suspension (2 ml intranasally and 2 ml orally) with a titer of $10^5$ TCID$_{50}$/50 $\mu$l.
2.5. Efficacy test

After an acclimatizing period of 10 days, 10 dogs were housed separately. Eight dogs, randomly chosen, were vaccinated by intramuscular injection (four dogs—group A) or by oronasal route (four dogs—group B), each with 2 ml of ML CCoV strain 257/98-3c. Two dogs were maintained non-vaccinated.

Following vaccination, the dogs were observed for any adverse local or systemic reactions and faecal samples were collected daily for 28 days post-vaccination (dpv).

Twenty-eight days later, the vaccinated and control dogs were challenged with CCoV strain 144/01. On the day of challenge, and for 28 days post-challenge (dpc), the dogs were examined clinically and virus shedding was monitored.

Because dogs are generally refractory to clinical disease after experimental infection with CCoV, protective immunity was assessed also by monitoring of virus shedding (median days of virus shedding). The experimental design is reported in Table 1.

2.6. Samples analysis

For virus isolation (VI), faecal samples were homogenized (10% w/v) in minimal essential medium (MEM). After centrifugation for 10 min at 4000 x g, 200 μl of the supernatant, with antibiotics (5000 IU/ml penicillin, 2500 μg/ml streptomycin, 10 μg/ml amphotericin B), were inoculated in duplicate onto freshly trypsinised A-72 cells in 24 well-plates containing glass slides. The cells were observed daily for cytopathic effects (cpe) and, after 72 h, were fixed with cold acetone and tested by an immunofluorescence test (IF) using a CCoV monoclonal antibody (gently supplied by Dr. Gilles Chappuis, Merial, France). Each sample was considered negative if cpe or IF was not observed after three serial passages.

Additionally, a PCR test (Pratelli et al., 1999a) was used to detect CCoV in faecal samples. Briefly, reverse transcription was performed in a total reaction volume of 20 μl containing PCR buffer 1X (KCl 50 mM, Tris–HCl 10 mM, pH 8.3, MgCl₂ 5 mM, 1 mM of each deoxynucleotide (dATP, dCTP, dGTP, dTTP), RNase 1 U, MuLV reverse transcriptase 2.5 U, random hexamers 2.5 U. Synthesis of cDNA was carried out at 42 °C for 30 min, followed by a denaturation step at 99 °C for 5 min. The mixture was brought up to a total volume of 100 μl containing PCR buffer 1X, MgCl₂ 2 mM, AmpliTaq Gold DNA polymerase 2.5 U and 50 pmol of each primer, CCoV1 and CCoV2. The PCR mixture was subjected to 35 cycles (94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min) in a DNA thermal cycler.

2.7. Serological tests

Blood samples were collected from the 10 dogs for serological tests on the day of vaccination and, later, on dpv 7, 14, 21 and 28. Additional samples were collected on the day of challenge and at 7, 14, 21 and 28 dpc. ELISA and virus neutralization tests were carried out as described (Elia et al., 2002; Pratelli et al., 2002b). VN titers are expressed as geometric means and OD values as median values.

2.8. Statistical analysis

Given the small size of the comparison groups and the non-normal distribution of data, as verified by the Kolmogorov–Smirnov test, the non-parametric Mann–Whitney U-test was used to compare the duration of CCoV shedding, the VN titers and the ELISA OD values after vaccination and after

---

Table 1

| Groups | Dogs | Vaccination route | Faecal sampling for VI and PCR | Serum sampling for VN and ELISA |
|--------|------|-------------------|-------------------------------|---------------------------------|
| A      | 4    | im                | Daily, for dpv 28 and dpc 28  | Weekly, for dpv 28 and dpc 28   |
| B      | 4    | o/n               | Daily, for dpv 28 and dpc 28  | Weekly, for dpv 28 and dpc 28   |
| Controls | 2  | no                | Daily, for dpc 28             | Weekly, for dpc 28              |

im: intramuscular; o/n: oronasal; VI: virus isolation; VN: virus neutralization test; dpv: days post-vaccination; dpc: days post-challenge; no: not vaccinated.
challenge. A $P$-value < 0.05 was considered as significant.

3. Results

3.1. Safety

Following intramuscular or oronasal inoculation of 10 times the vaccinal dose, all dogs remained normal and alert throughout the observation period and no local or generalized reactions to the vaccine were observed. WBC counts, performed daily in order to evaluate total leukocyte, remained normal.

Table 3

Results of the efficacy test in dogs after CCoV vaccination (a) and CCoV challenge (b)

| Group | Dogs | Virus shedding |
|-------|------|----------------|
|       |      | VI PCR Onseta Duration Mean b | Onsetc Duration Mean c |
| (a) CCoV vaccination | | | |
| Group A | 1 | nd | nd | 2 6 6 | 1 4 6 5.5 |
|         | 2 | nd | nd | 2 6 | 1 2 2 2 |
|         | 3 | nd | nd | 2 6 | 1 2 2 2 |
|         | 4 | nd | nd | 2 6 | 1 2 2 2 |
| Group B | 1 | nd | nd | 2 6 6 | 1 4 6 5.5 |
|         | 2 | nd | nd | 2 6 | 1 2 2 2 |
|         | 3 | nd | nd | 2 6 | 1 2 2 2 |
|         | 4 | nd | nd | 2 6 | 1 2 2 2 |

| (b) CCoV challenge | | | |
|                   | | | |
| Group A | 1 | 4 | 6 | 5.5 | 2 11 10 |
|         | 2 | 4 | 5 | 2 7 8 |
|         | 3 | 4 | 5 | 2 9 |
|         | 4 | 4 | 7 | 2 11 |
| Group B | 1 | nd | nd | 2 6 | 1 2 2 2 |
|         | 2 | nd | nd | 2 6 | 1 2 2 2 |
|         | 3 | nd | nd | 2 6 | 1 2 2 2 |
|         | 4 | nd | nd | 2 6 | 1 2 2 2 |
| Control  | 1 | 3 | 14 | 14.5 | 1 22 23 |
|          | 2 | 3 | 15 | 15.5 | 1 22 23 |

Table 2

Results of the safety test of the CCoV vaccine in dogs

| Dogs | Route | Virus shedding (days) | Antibodies (dpv 28) |
|------|-------|-----------------------|--------------------|
|      | VI PCR | VN ELISA              |                    |
| 1    | im 0 0 | 4 0.152               |                    |
| 2    | im 0 0 | 8 0.164               |                    |
| 3    | o/n 0 6 | 8 0.190              |                    |
| 4    | o/n 0 6 | 8 0.215              |                    |

im: intramuscular; o/n: oronasal; VI: virus isolation; VN: virus neutralization titer; dpv: days post-vaccination.

Virus isolation and PCR assay performed on the faecal samples of the two dogs inoculated by intramuscular route were negative. The faecal samples of the two dogs inoculated by oronasal route were PCR

Table 2

Results of the safety test of the CCoV vaccine in dogs

| Dogs | Route | Virus shedding (days) | Antibodies (dpv 28) |
|------|-------|-----------------------|--------------------|
|      | VI PCR | VN ELISA              |                    |
| 1    | im 0 0 | 4 0.152               |                    |
| 2    | im 0 0 | 8 0.164               |                    |
| 3    | o/n 0 6 | 8 0.190              |                    |
| 4    | o/n 0 6 | 8 0.215              |                    |

im: intramuscular; o/n: oronasal; VI: virus isolation; VN: virus neutralization titer; dpv: days post-vaccination.

Virus isolation and PCR assay performed on the faecal samples of the two dogs inoculated by intramuscular route were negative. The faecal samples of the two dogs inoculated by oronasal route were PCR

Virus isolation and PCR assay performed on the faecal samples of the two dogs inoculated by intramuscular route were negative. The faecal samples of the two dogs inoculated by oronasal route were PCR
positive for 6 days, starting from dpv 2 to 7. Serological tests (VN and ELISA) carried out at dpv 28 indicated that all dogs had developed CCoV antibody titers (Table 2).

3.2. Efficacy in dogs vaccinated by intramuscular route (group A)

After vaccination, VI of the faecal samples was negative in all the dogs (Table 3a). By the VN test, at dpv 28 all dogs had slight increases (1:4) in VN antibody titers. By ELISA test, the highest antibody values were observed at dpv 28 (OD = 0.143) (Fig. 1).

After the challenge, the vaccinated dogs displayed no clinical signs and they shed virus for 5.5 days (median value) from dpv 4 to 10. By PCR, CCoV was detected for 10 days (median value), starting from dpv 2 to 12 (Table 3b). Antibody titers in the vaccinated dogs, as evaluated by VN test, increased progressively to 1:64 (three dogs) and 1:128 (one dog) (geometric mean = 75.9) at dpv 28. ELISA test showed progressively increasing OD values, reaching the highest values at dpv 28 (OD = 0.211) (Fig. 1).

3.3. Efficacy in dogs vaccinated by oronasal route (group B)

After vaccination, VI of faecal samples was negative, while the PCR assay revealed CCoV in the samples for 6 days (median value) from dpv 2 to 7 (Table 3a). By VN test, antibodies reached values of 1:8 between dpv 21 and 28. By ELISA test, antibodies reached the highest value at dpv 28 (OD = 0.210) (Fig. 1).

After challenge, the vaccinated dogs did not have any clinical signs or virus shedding by either VI or PCR assays (Table 3b). However, there was seroconversion in all dogs by both VN and ELISA tests, with VN titers 1:16 (two dogs) and 1:32 (two dogs) (geometric mean = 22.4) and OD = 0.225, at 28 dpc (Fig. 1).

3.4. Unvaccinated dogs (controls)

The two control dogs inoculated with the field strain developed hyperthermia from dpv 2 to 4 and mild diarrhoea from dpv 3 to 6. In the faecal samples, virus was isolated, respectively, from dpv 3 to
16–17 (median value = 14.5). By PCR, virus was detected, respectively, from dpc 1 to 22–24 (median value = 23) (Table 3b).

Antibodies by VN test increased at 28 dpc (geometric mean = 22.4). By ELISA test the highest OD values were reached at dpc 28 (OD median value = 0.250) (Fig. 1).

3.5. Statistical analysis

The length of CCoV shedding as well as the antibody levels detected by VN and by ELISA tests after vaccination showed statistically significant differences between groups A and B. The *P*-value of the Mann–Whitney *U*-test was 0.029 for all comparisons. Statistically significant differences were observed after CCoV challenge, between groups A and B, regarding the length of CCoV shedding, as detected by VI and by PCR, and in regarding the VN antibody titers (the *P*-value of the Mann–Whitney *U*-test was 0.029 in all cases).

Differences in length of viral shedding between group A and control dogs (*P* = 0.133) and between group B and control dogs (*P* = 0.067) were not significant.

4. Discussion

In the present study we report the safety and the efficacy of a ML CCoV vaccine in dogs. No local or systemic adverse reactions were observed in the vaccinated dogs. After vaccination, infectious virus was not detected in faecal samples by VI or CCoV nucleic acid by the PCR assay in dogs inoculated by the intramuscular route (group A). However, virus nucleic acid was revealed by PCR for six median days in the dogs inoculated by the oronasal route (group B), suggesting low viral titers or viral remnants in the samples (Pratelli et al., 1999a). In general, the efficacy of the vaccine appeared satisfactory. Considering that the protection against coronavirus infections has been generally correlated with the presence of specific antibodies in the mucosal surface (Ogra et al., 1980; Saif, 1996; Murphy, 1999), a significant difference was observed between dogs of groups A (intramuscular vaccination) and B (oronasal vaccination) (*P* = 0.029).

It should be stressed that no CCoV shedding, after challenge, was observed by either VI or PCR in the dogs vaccinated by oronasal route (group B). The sera of dogs from group A showed high OD values in the ELISA test, confirming that this test is substantially more sensitive than the VN test in detecting antibodies to CCoV (Pratelli et al., 2002b). After CCoV challenge, evaluation of the reduction of challenge virus shed in faeces revealed a decrease in virus in the vaccinated dogs, compared with the control dogs.

In the dogs vaccinated by oronasal route (group B) high antibody values were detected by the ELISA test. Protection from CCoV infection was complete since challenge virus was never detected by VI or by PCR assay. It seems plausible that the protection observed in the vaccinated groups might be modulated by the production of mucosal IgA (Ogra et al., 1980; Murphy, 1999).

We do not have data on the production of faecal IgA in dogs after intramuscular or oronasal administration of ML CCoV vaccine. However, it may be speculated that dogs vaccinated by the intramuscular route had low levels of faecal IgA which provided partial protection to challenge, but insufficient to confer complete protection as observed in TGEV pigs (Saif, 1996).

While the immune mechanisms of the protection from CCoV infection are still not clear, we can hypothesize that a ML vaccine inoculated by the oronasal route might generate a strong IgA production in the gut conferring a complete protection from the infection. The results of this study are interesting for several reasons. CCoV infection alone is considered of minor clinical relevance, but in the past, dual infections between CCoV and CPV2 (Pratelli et al., 1999b) and CCoV and CAdV1 (Pratelli et al., 2001) have been observed in dogs that had severe clinical illness due to the enhanced pathogenicity of dual infections. Polymicrobial infections are common in high density populations, such as unvaccinated kennels.

An additional epidemiological consideration is related to recent findings where CCoV shedding in the faeces of infected pups occurred over a period of 37 days (Pratelli et al., 2001). It, therefore, seems likely that immunization of dogs against CCoV would have positive epidemiological effects.

Our studies suggest that effective vaccines which are able to induce truly protective and long-lived
immunity to infection should be sought to control the spread of CCoV in high risk dog populations.

Acknowledgements

This work was supported by grants from Ministry of University, Italy (project: Entiteri virali del cane).

References

Appel, M.J.G., 1988. Does canine coronavirus augment the effect of subsequent parvovirus infection? Vet. Med. 83, 386–396.

Carmichael, L.E., 1997. Vaccines for dogs. In: Pastoret, P.-P., Appel, M.J.G., 1988. Does canine coronavirus augment the effect of subsequent parvovirus infection? Vet. Med. 83, 386–396.

Enjuanes, L., Brian, D., Cavanagh, D., Holmes, K., Lai, M.M.C., Elia, G., Decaro, N., Tinelli, A., Martella, V., Pratelli, A., de Vries, A.A.F., Horzinek, M.C., Rottier, P.J.M., de Groot, R.J., Carmichael, L.E., Buonavoglia, C., 2002. Evaluation of antibody response to canine coronavirus infection in dogs by Western blotting analysis. New Microbiol. 25, 275–281.

Laude, H., Masters, P., Rottier, P., Siddell, S., Spaan, W.J.M., Carstens, E.B., Estes, M.K., Lemon, S.M., Maniloff, J., Mayo, M.A., McGeoch, D.J., Pringle, R.B. (Eds.), Virus Taxonomy, Classification and Nomenclature of Viruses. Academic Press, New York, pp. 835–849.

Pratelli, A., Martella, V., Elia, G., Tempesta, M., Guarda, F., Capucchio, M.T., Carmichael, L.E., Buonavoglia, C., 2001. Severe enteric disease in an animal shelter associated with dual infections by canine adenovirus type 1 and canine coronavirus. J. Vet. Med. B 48, 345–349.

Pratelli, A., Elia, G., Martella, V., Tinelli, F., Decaro, N., Marsilio, F., Buonavoglia, D., Tempesta, M., Buonavoglia, C., 2002a. M gene evolution of canine coronavirus in naturally infected dogs. Vet. Res. 31, 151–176.

Pratelli, A., Elia, G., Martella, V., Tinelli, F., Decaro, N., Marsilio, F., Buonavoglia, D., Tempesta, M., Buonavoglia, C., 2002b. M gene expression of canine coronavirus vaccine in pups. New Microbiol. 26, 151–155.

Tennant, B.J.R., Gaskell, M., Kelly, D.F., Carter, S.C., Gasell, C.J., 1991. Canine coronavirus infection in dog following corona inoculation. Res. Vet. Sci. 51, 11–18.

Wilson, R.B., Holladay, J.A., Cote, J.A., 1986. A neurologic syndrome associated with use of a canine coronavirus–parvovirus vaccine in dogs. Comp. Cont. Educ. Pract. Vet. 8, 117–122.

Woods, R.D., Wesley, R.D., Kapke, P.A., 1987. Complement-dependent neutralization of transmissible gastroenteritis virus by monoclonal antibodies. Adv. Exp. Med. Biol. 218, 493–500.